References
1. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007;357:380-390.
2. Kaplan SL. Community-acquired methicillin-resistant Staphylococcus aureus infections in children. Semin Pediatr Infect Dis 2006;17:113-119.
3. Zetola N, Francis JS, Nuermberger EL, et al. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5:275-286.
4. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis 1999;29:259-263.
5. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984.
6. Golding GR, Levett PN, McDonald RR, et al. High rates of Staphylococcus aureus USA400 infection, northern Canada. Emerg Infect Dis 2011;17:722-725.
7. Stenstrom R, Grafstein E, Romney M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in a Canadian emergency department. CJEM 2009;11:430-438.
8. Matlow A, Forgie S, Pelude L, et al. National surveillance of methicillin-resistant Staphylococcus aureus among hospitalized pediatric patients in Canadian acute care facilities, 1995-2007. Pediatr Infect Dis J 2012;31:814-820.
9. Embil J, Ramotar K, Romance L, et al. Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992. Infect Control Hosp Epidemiol 1994;15:646-651.
10. Shahin R, Johnson IL, Jamieson F, et al. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease. Toronto Child Care Center Study Group. Arch Pediatr Adolesc Med 1999;153:864-868.
11. Adam HJ, Allen VG, Currie A, et al. Community-associated methicillin-resistant Staphylococcus aureus: prevalence in skin and soft tissue infections at emergency departments in the Greater Toronto Area and associated risk factors. CJEM 2009;11:439-446.
12. Kurbis CA, Wylie JL. Community-based cluster of methicillin-resistant Staphylococcus aureus in Manitoba. Can J Infect Dis 2001;12:149-152.
13. Wylie JL, Nowicki DL. Molecular epidemiology of community- and health care-associated methicillin-resistant Staphylococcus aureus in Manitoba, Canada. J Clin Microbiol 2005;43:2830-2836.
14. Christianson S, Golding GR, Campbell J, et al. Comparative genomics of Canadian epidemic lineages of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2007;45:1904-1911.
15. Muileboom J, Hamilton M, Parent K, et al. Community-associated methicillin-resistant Staphylococcus aureus in northwest Ontario: a fiveyear report of incidence and antibiotic resistance. Can J Infect Dis Med Microbiol 2013;24:e42-e44.
16. Peebles E, Morris R, Chafe R. Community-associated methicillin-resistant Staphylococcus aureus in a pediatric emergency department in Newfoundland and Labrador. Can J Infect Dis Med Microbiol 2014;25:13-16.
17. Gonzales C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-1177.
18. Martınez-Aguilar G, Hammerman WA, Mason EO Jr, et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003;22:593-598.
19. Hulten KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated Staphylococcus aureus infections in children. Pediatr Infect Dis J 2006;25:349-353.
20. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-e55.
21. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007;51:4044-4048.
22. Chen AE, Carroll KC, Diener-West M, et al. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics 2011;127:e573-e580.